A novel approach to glioma therapy using an oncolytic adenovirus with two specific promoters

  • Authors:
    • Feng Liu
    • Kaya Xu
    • Hua Yang
    • Yuming Li
    • Jian Liu
    • Jixiang Wang
    • Zhizhong Guan
  • View Affiliations

  • Published online on: December 21, 2017     https://doi.org/10.3892/ol.2017.7684
  • Pages: 3362-3368
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gliomas are the most common type of primary brain tumor in adults, where more than half of the cases are malignant, and the prognosis is poor. The early viral 1A (E1A) protein has been widely recognized to be essential for adenoviral replication and production of progeny virions in human cells, a process that is regulated by human telomerase reverse transcriptase. The p53 gene, as a tumor suppressor, regulates diverse cellular processes, including cell cycle arrest, cell autophagy, senescence and apoptosis. Dysfunction of the p53 pathways is common in malignant gliomas. Exogenous expression of p53 during adenovirus replication in human cancer cells may accelerate cell death and improve the release of early virus progeny. In the present study, a conditionally replicative adenovirus (CRAd) Ad‑Tp‑E1A‑Gp‑p53, which expressed functional p53 protein when replicating in cancer cells, was constructed. Next, the level of p53 expression in U251 cells was determined by western blot analysis, and the inhibitory effect of Ad‑Tp‑E1A‑Gp‑p53 on U251 cells was detected via an MTT assay. The results indicated that p53 expression was upregulated with an increase in the multiplicity of infection (MOI) of Ad‑Tp‑E1A‑Gp‑p53. Additionally, the inhibitory effects of Ad‑Tp‑E1A‑Gp‑p53 in different groups were significantly different (P<0.05), with the inhibition ratio of the experimental groups being higher, compared with the control group (P<0.05). Furthermore, the inhibition ratio increased with increases in the MOI of Ad‑Tp‑E1A‑Gp‑p53. Therefore, the expression of functional p53 and that of E1A may increase the potency of CRAd, and overexpression of p53 through CRAd is a promising approach to more effective treatments in a number of human cancer types.
View Figures
View References

Related Articles

Journal Cover

March-2018
Volume 15 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu F, Xu K, Yang H, Li Y, Liu J, Wang J and Guan Z: A novel approach to glioma therapy using an oncolytic adenovirus with two specific promoters. Oncol Lett 15: 3362-3368, 2018
APA
Liu, F., Xu, K., Yang, H., Li, Y., Liu, J., Wang, J., & Guan, Z. (2018). A novel approach to glioma therapy using an oncolytic adenovirus with two specific promoters. Oncology Letters, 15, 3362-3368. https://doi.org/10.3892/ol.2017.7684
MLA
Liu, F., Xu, K., Yang, H., Li, Y., Liu, J., Wang, J., Guan, Z."A novel approach to glioma therapy using an oncolytic adenovirus with two specific promoters". Oncology Letters 15.3 (2018): 3362-3368.
Chicago
Liu, F., Xu, K., Yang, H., Li, Y., Liu, J., Wang, J., Guan, Z."A novel approach to glioma therapy using an oncolytic adenovirus with two specific promoters". Oncology Letters 15, no. 3 (2018): 3362-3368. https://doi.org/10.3892/ol.2017.7684